Kondo Y - Search Results

1

Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component.

Kondo Y, Koga S, Komata T, Kondo S. Kondo Y, et al. Among authors: kondo s. Oncogene. 2000 Apr 27;19(18):2205-11. doi: 10.1038/sj.onc.1203538. Oncogene. 2000. PMID: 10822370

2

A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter.

Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. Koga S, et al. Among authors: kondo s, kondo y. Hum Gene Ther. 2000 Jul 1;11(10):1397-406. doi: 10.1089/10430340050057477. Hum Gene Ther. 2000. PMID: 10910137

3

2-5A antisense telomerase RNA therapy for intracranial malignant gliomas.

Mukai S, Kondo Y, Koga S, Komata T, Barna BP, Kondo S. Mukai S, et al. Among authors: kondo s, kondo y. Cancer Res. 2000 Aug 15;60(16):4461-7. Cancer Res. 2000. PMID: 10969793

4

Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.

Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S. Komata T, et al. Among authors: kondo s, kondo y. Gene Ther. 2000 Dec;7(24):2071-9. doi: 10.1038/sj.gt.3301327. Gene Ther. 2000. PMID: 11223987

5

Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA.

Koga S, Kondo Y, Komata T, Kondo S. Koga S, et al. Among authors: kondo s, kondo y. Gene Ther. 2001 Apr;8(8):654-8. doi: 10.1038/sj.gt.3301449. Gene Ther. 2001. PMID: 11320413

6

Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas.

Kondo Y, Komata T, Kondo S. Kondo Y, et al. Among authors: kondo s. Int J Oncol. 2001 Jun;18(6):1287-92. doi: 10.3892/ijo.18.6.1287. Int J Oncol. 2001. PMID: 11351264

7

Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.

Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S, Kondo S. Komata T, et al. Among authors: kondo s, kondo y. Cancer Res. 2001 Aug 1;61(15):5796-802. Cancer Res. 2001. PMID: 11479218

8

FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo.

Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. Koga S, et al. Among authors: kondo s, kondo y. Anticancer Res. 2001 May-Jun;21(3B):1937-43. Anticancer Res. 2001. PMID: 11497281

9

A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter.

Komata T, Koga S, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S, Kondo Y. Komata T, et al. Among authors: kondo s, kondo y. Int J Oncol. 2001 Nov;19(5):1015-20. doi: 10.3892/ijo.19.5.1015. Int J Oncol. 2001. PMID: 11605003

10

Association between telomerase activity and basic fibroblast growth factor up-regulation in retinoblastomas.

Kondo Y, Tanaka Y, Shields JA, Kondo S. Kondo Y, et al. Among authors: kondo s. Anticancer Res. 2001 Nov-Dec;21(6A):3765-72. Anticancer Res. 2001. PMID: 11911245

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,187 results

Search Page

Filters